Skip to main content

Table 1 Multivariable analysis of factors associated with intravenous macrolide treatment

From: Oral versus intravenous clarithromycin in moderate to severe community-acquired pneumonia: an observational study

Variable Odds ratio (95% CI), p-value
Gender (male) 0.79 (0.55–1.13), p = 0.2
Age 1.01 (0.99–1.03), p = 0.1
Congestive cardiac failure 0.83 (0.51–1.35), p = 0.5
Liver disease 0.94 (0.44–2.00), p = 0.9
Stroke 1.23 (0.68–2.22), p = 0.5
COPD 0.80 (0.52–1.23), p = 0.3
Diabetes 1.06 (0.63–1.80), p = 0.8
Smoking status 1.04 (0.71–1.52), p = 0.8
CURB-65 score 1.13 (0.90–1.41), p = 0.3
Temperature 1.07 (0.89–1.29), p = 0.5
Pulse rate 1.0 (0.99–1.01), p = 0.4
Prior statin use 1.11 (0.71–1.75), p = 0.7
Antiplatelets 1.01 (0.65–1.56), p = 0.9
ACE inhibitors/ARBs 0.90 (0.56–1.45), p = 0.7
Beta-lactam co-administration 0.89 (0.56–1.41), p = 0.6
Corticosteroid use 0.90 (0.49–1.66), p = 0.7
Sodium level 0.99 (0.95–1.03), p = 0.5
Haemoglobin 1.00 (0.99–1.01), p = 0.4
White cell count 1.01 (0.99–1.02), p = 0.3
Platelet count 1.00 (0.99–1.00), p = 0.8
Albumin 1.0 (0.49–1.66), p = 0.7
Multilobar radiographic changes 1.14 (0.73–1.79), p = 0.6
Antibiotic treatment prior to admission 1.67 95% CI 0.96–2.92), p = 0.08
  1. COPD chronic obstructive pulmonary disease, ACE inhibitors, angiotensin-converting-enzyme inhibitors, ARBs, angiotensin receptor blockers